Investor Presentaiton
Investor Presentation
First six months of 2018
Strong underlying insulin market growth and sustained
global volume market share
Global insulin market
Slide 45
Global modern and new-generation insulin
volume market shares
Novo Nordisk
Sanofi
-
Eli Lilly
Device penetration
Modern insulin penetration¹
tMU
500
CAGR volume¹: 4.8%
Penetration
CAGR value¹: 15.3%
100%
60%
50%
400
80%
40%
300
60%
MI and NGI²
30%
200
Market value³: DKK 218 billion
- 40%
20%
100
Human insulin
20%
10%
Market value²: DKK 23 billion
0
0%
0%
May
2013
May
2018
1 CAGR for 5-year period; 2MI: Modern insulin. NGI: New-generation insulin
3Annual value of total insulin class
Note: Data is sensitive to changes in IQVIA data collection and reporting methodology
Source: IQVIA monthly MAT May, 2018 volume and value (DKK) figures
changing
diabetes®
May
2013
Note: Data is sensitive to changes in IQVIA data collection and reporting methodology,
does not add up to 100% as only selected pharmaceutical companies are included
Source: IQVIA monthly MAT May, 2018 volume figures
45%
33%
20%
May
2018
novo nordiskView entire presentation